Immutep Ltd Sponsored ADR IMMP 深 滬
已收盤 02-06 16:00:00 美东时间
2.62
0.000
0.00%
華盛通- 最 高2.675
- 今 開2.65
- 成交量 15.65万股
- 最 低 2.56
- 昨 收 2.62
- 總市值 3.86亿
- 52周最高 3.5299
- 市盈率 靜 --
- 換手率 0.11%
- 52周最低 1.32
- 委 比 16.67%
- 總股本 1.47亿
- 歷史最高 7.95
- 量 比 0.79
- 振 幅 4.39%
- 歷史最低 0.53
- 每 手 1
- 風險率 0.43%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Immutep Achieves 50% Participant Enrollment Target In TACTI-004 Phase III Study Evaluating Eftilagimod Alfa In Combination With Merck's Anti-PD-1 Therapy
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces it has achieved 50% of the patient enrolment target in
02-06 21:04
Immutep Quarterly Activities Report Q2 FY26
Immutep collaborates with Dr. Reddy’s for global commercialisation of eftilagimod alfa (efti), receiving A$30 million upfront and potential A$528 million in milestones. Phase III trial TACTI-004 shows strong progress, with efti combination outperforming historical controls in NSCLC. INSIGHT-003 data highlight high response rates across PD-L1 levels. EFTISARC-NEO met primary endpoint in soft tissue sarcoma. AIPAC-003 shows promising results in bre...
01-29 13:00
Immutep Secures Dr. Reddy’s Partnership and Strengthens Clinical, Financial Position
Immutep Ltd ( ($AU:IMM) ) has provided an update. Immutep reported a pivotal qu...
01-29 11:28
Immutep Reports Operational Progress In TACTI-004 Phase III Trial Evaluating Eftilagimod Alfa In Combination With MSD's Anti-PD-1 Therapy, KEYTRUDA, And Chemotherapy As First Line Therapy For Advanced/Metastatic Non-Small Cell Lung Cancer
The registrational TACTI-004 Phase III has enrolled 289 patients globally, over 38% of the trial's targeted enrolmentStrong operational progress continues globally with over 120 activated clinical sites and 27 countries
2025-12-16 21:02
Immutep Announces Strong Operational Progress in Global TACTI-004 (KEYNOTE-F91) Phase III and Enrolment Continues at Robust Pace
Immutep reports strong progress in TACTI-004 Phase III trial with 289 patients enrolled (38% of target). Over 120 clinical sites activated across 27 countries, including the US, with regulatory approvals secured. Futility analysis on track for Q1 2026, with enrollment expected to complete by Q3 2026. CEO Marc Voigt highlights growing interest and commitment to upcoming milestones.
2025-12-16 13:00
美股牛股 | “减肥神药”临床数据引爆！WaVe生命科学涨超147%，硕迪生物涨超102%；Confluent涨超29%
“减肥神药”临床数据引爆！WaVe生命科学涨超147%，硕迪生物涨超102%；Confluent涨超29%，IBM拟110亿美元收购该公司>>
2025-12-09 17:40
Immutep to Present New Data from AIPAC-003 Phase II at the 2025 San Antonio Breast Cancer Symposium
Immutep的AIPAC-003试验数据显示，eftilagimod alfa（efti）联合paclitaxel在治疗HR+和HER2阴性/低转移性乳腺癌患者中表现出显著的客观缓解率（ORR）和疾病控制率（DCR）。30mg剂量组达到41.9%的ORR和87.1%的DCR，90mg剂量组分别为48.5%和78.8%。此外，两个剂量均显示免疫激活生物标志物的显著增加。基于FDA的Project Optimus要求，30mg剂量被确定为最佳生物剂量（OBD）。90mg剂量耐受性较差，包括剂量限制毒性（DLT）和注射部位反应。这些结果将支持efti在非小细胞肺癌及其他癌症中的进一步开发。
2025-12-02 13:00
Immutep Data From EFTISARC-NEO Study Evaluating Eftilagimod Alfa With Radiotherapy Plus KEYTRUDA Exceeds Prespecified Level Of Pathologic Response Rates, Reaches Median 51.5% Tumor Hyalinization/Fibrosis
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces positive data from the EFTISARC-NEO trial that were
2025-11-13 21:02
Translational Data and Significant Pathologic Response Rates from EFTISARC-NEO Phase II Highlighted in Oral Presentation at CTOS 2025
<p>Immutep Limited的EFTISARC-NEO试验显示，新型eftilagimod alfa（efti）联合放疗和KEYTRUDA®在可切除软组织肉瘤（STS）的 neoadjuvant治疗中取得了显著成效，肿瘤透明化/纤维化率高达51.5%，超出预期。研究涵盖10种STS亚型，尤其对罕见、高度恶性的肿瘤显示良好效果。早期数据表明，治疗显著激活免疫系统，关键细胞因子如CXCL9、CXCL10、IL-23和IFN-γ水平显著上升，与病理反应相关。研究结果为患者提供了更优生存机会，并获Golden Scalpel奖认可，进一步证实efti在治疗早期癌症中的潜力。</p>
2025-11-13 13:00
Immutep Secures A$4.6 Million R&D Tax Incentive from French Government
Immutep Ltd ( ($AU:IMM) ) has issued an update. Immutep Limited has received a ...
2025-11-03 08:08
